Summary
Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4) Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22–153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beirewaltes, WH (1987). Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and prospectives. Med Pediatr Oncol 15: 188–191.
Bolster, A, Hilditch, TE, Wheldon, TE, Gaze, MN & Barrett, A (1995). Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children. Br J Radiol 68: 481–490.
Buck, J, Bruchelt, G & Girgert, R (1985). Specific uptake of m (125) iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 45: 6366–6370.
Brodeur, GM, Pritchard, J, Berthold, F, Carsen, NLT, Castel, V, Castelberry, RP, De Bernardi, B, Evans, AE & Favrot, M et al (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466–1477.
Castleberry, RP, Kun, LE, Shuster, JJ, Altshuler, G, Smith, IE, Nitschke, R, Wharam, M, McWilliams, N, Joshi, V & Hayes, FA (1991). Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 19: 789–795.
De Bernardi, B, Carli, M, Casale, F, Corciulo, P, Cordero di Montezemolo, L, De Laurentis, C, Bagnulo, S, Brisigotti, M, Marchese, N, Garaventa, A & Felici, L (1992). Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for neuroblastoma. J Clin Oncol 10: 1870–1878.
Flower, MA & Fielding, SL (1996). Radiation dosimetry for 131I-MIBG therapy of neuroblastoma. Phys Med Biol 41: 1933–1940.
Garaventa, A, Guerra, P, Arrighini, A, Bertolazzi, L, Bestagno, M, De Bernardi, B, Lanino, E, Villavecchia, GP & Claudiani, F (1991). Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer 67: 922
Garaventa, A, De Bernardi, B, Pianca, C, Donfrancesco, A, Cordero di Montezemolo, L, Di Tullio, MT, Bagnulo, S, Mancini, A, Carli, M, Pession, A, Arrighini, A, Di Cataldo, A, Tamaro, P, Iasonni, V, Taccone, A, Rogers, D & Boni, L (1993). Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. J Clin Oncol 9: 1770–1779.
Gaze, MN, Wheldon, T, O'Donoghue, JA, Hilditch, TE, McNee, SG, Simpson, E & Barrett, A (1995). Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 31: 252–256.
Geatti, O, Shapiro, B, Sisson, JC, Hutchinson, RJ, Malette, S, Eyre, P & Beierwaltes, WH (1985). Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 26: 736–742.
Haase, GM, Atkinson, JB, Stram, DO, Lukens, JN & Matthay, KK (1995). Surgical management and outcome of locoregional neuroblastoma: comparison of the Children Cancer Group and the International Staging System. J Pediatr Surg 30: 289–295.
Italian Society of Pediatric Oncology Italian Society of Radiology Nuclear Medicine, Italian Society of Biology and Nuclear Medicine and Associazione Genitori Oncologia Pediatrica (1987). International Workshop in Pediatric Oncology: the role of MIBG in therapy and diagnosis and monotoring of neuroblastoma. Rome 1986. Med Pediatr Oncol 17,
Jaques, S, Tobes, MC & Sisson, JC (1987). Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured pheochromocytoma cells: evidence for uptake on. Cancer Res 47: 3920–3928.
Klingebiel, T, Treuner, J, Ehninger, G, Keller, KD, Dopfer, R, Feine, U & Niethammer, D (1989). [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Cancer Chemother Pharmacol 25: 143–148.
Lashford, LS, Lewis, IJ, Fielding, SL, Flower, MA, Meller, S, Kemshead, JT & Ackery, D (1992). Phase I/II study of iodine 131metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children Cancer Study Group investigation. J Clin Oncol 10: 1889–1896.
Leavey, PJ, Odom, LF, Poole, M, McNeely, L, Weslie Tyson, R & Haase, GM (1997). Intra-operative radiation therapy in pediatric neuroblastoma. Med Pediatr Oncol 28: 424–428.
Mastangelo, R, Lasorella, A, Iavarone, A, Rufini, V, Troncone, L, Danza, F & Riccardi, R (1993). Critical observation on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med Pediatr Oncol 21: 411–415.
Mastrangelo, R, Tornesello, A & Mastrangelo, S (1998). Role of 131metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol 31: 22–26.
Matthay, KK, De Santes, K & Hasegawa, B (1998). Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16: 229–236.
Montaldo, PG, Lanciotti, M, Casalaro, A, Cornaglia-Ferraris, P & Ponzoni, M (1991). Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res 51: 4342–4346.
Philip, T, Ladenstein, R, Lasset, C, Hartmann, O, Zucker, JM, Pinkerton, R, Pearson, ADJ, Klingebiel, T, Garaventa, A, Kremens, B, Bernard, JL, Rosti, G & Chauvin, F (1997). 1070 Myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. Eur J Cancer 33: 2130–2135.
Powis, MR, Imerson, JD & Homes, SJK (1996). The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group. J Pediatr Surg 31: 516–519.
Press, OW, Eary, JF, Appelbaum, FR, Martin, PJ, Nelp, WB, Glenn, S, Fisher, DR, Porter, B, Matthews, DC, Gooley, T & Bernstein, ID (1995). Phase II trial of I131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336–340.
Schwabe, D, Sahm, St, Gerein, V, Happ, J, Kropp-v Rabenau, H, Maul, F, Baum, RP, Mangold, K, Nitz, C, Hör, G & Kornhuber, B (1987). 131-metaiodobenzylguanidine therapy of neuroblastoma in childhood. Eur J Pediatr 146: 246–250.
Sisson, JC, Shapiro, B, Hutchinson, RJ, Shulkin, BL & Zempel, S (1996). Survival of patients with neuroblastoma treated with I125-MIBG. Am J Clin Oncol 19: 144–148.
Van Hasselt, EJ, Heij, HA, De Kraker, J, Vos, A & Voûte, PA (1996). Pretreatment with [131I]metaiodobenzylguanidine and surgical resection of advanced neuroblastoma. Eur J Pediatr Surg 6: 155–159.
Weber, W, Weber, J & Senekowitsch-Schmidtke, R (1996). Therapeutic effect of m-[131I]- and m-[125I] iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res 56: 5428–5434.
WHO (1979). WHO Handbook for Reporting Results of Cancer Treatment, WHO: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Garaventa, A., Bellagamba, O., Piccolo, M. et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 81, 1378–1384 (1999). https://doi.org/10.1038/sj.bjc.6694223
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6694223
Keywords
This article is cited by
-
The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis
BMC Cancer (2022)
-
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours
EJNMMI Physics (2020)
-
Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
European Journal of Nuclear Medicine and Molecular Imaging (2019)
-
Current Consensus on I-131 MIBG Therapy
Nuclear Medicine and Molecular Imaging (2018)
-
Monte Carlo simulation of the RBE of I-131 radiation using DNA damage as biomarker
Australasian Physical & Engineering Sciences in Medicine (2017)
